Amanda J Wade1, Joseph S Doyle1,2, Edward Gane3, Catherine Stedman4,5, Bridget Draper1, David Iser2, Stuart K Roberts6,7, William Kemp6,7, Dennis Petrie8, Nick Scott1,9, Peter Higgs1,9,10, Paul A Agius1,9,11, Janine Roney2, Lisa Stothers12, Alexander J Thompson12,13, Margaret E Hellard1,2,9. 1. Disease Elimination Program, Burnet Institute, Melbourne, Australia. 2. Department of Infectious Diseases, The Alfred, Melbourne, Australia. 3. New Zealand Liver Transplant Unit, Auckland City Hospital, Christchurch, New Zealand. 4. Department of Gastroenterology, Christchurch Hospital, Christchurch, New Zealand. 5. University of Otago, Christchurch, New Zealand. 6. Department of Gastroenterology, The Alfred. 7. Department of Medicine, Monash University. 8. Centre for Health Economics, Monash University. 9. School of Public Health and Preventive Medicine, Monash University, Melbourne. 10. Department of Public Health, La Trobe University, Bundoora. 11. Judith Lumley Centre, La Trobe University. 12. Department of Gastroenterology, St Vincent's Hospital. 13. Department of Medicine, University of Melbourne, Melbourne, Australia.
Abstract
BACKGROUND: To achieve the World Health Organization hepatitis C virus (HCV) elimination targets, it is essential to increase access to direct-acting antivirals (DAAs), especially among people who inject drugs (PWID). We aimed to determine the effectiveness of providing DAAs in primary care, compared with hospital-based specialist care. METHODS: We randomized PWID with HCV attending primary care sites in Australia or New Zealand to receive DAAs at their primary care site or local hospital (standard of care [SOC]). The primary outcome was to determine whether people treated in primary care had a noninferior rate of sustained virologic response at Week 12 (SVR12), compared to historical controls (consistent with DAA trials at the time of the study design); secondary outcomes included comparisons of treatment initiation, SVR12 rates, and the care cascade by study arm. RESULTS: We recruited 140 participants and randomized 136: 70 to the primary care arm and 66 to the SOC arm. The SVR12 rate (100%, 95% confidence interval [CI] 87.7-100) of people treated in primary care was noninferior when compared to historical controls (85% assumed). An intention-to-treat analysis revealed that the proportion of participants commencing treatment in the primary care arm (75%, 43/57) was significantly higher than in the SOC arm (34%, 18/53; P < .001; relative risk [RR] 2.48, 95% CI 1.54-3.95), and the proportion of participants with SVR12 was significantly higher in the primary care arm, compared to in the SOC arm (49% [28/57] and 30% [16/53], respectively; P = .043; RR 1.63, 95% CI 1.0-2.65). CONCLUSIONS: Providing HCV treatment in primary care increases treatment uptake and cure rates. Approaches that increase treatment uptake among PWID will accelerate elimination strategies. CLINICAL TRIALS REGISTRATION: NCT02555475.
RCT Entities:
BACKGROUND: To achieve the World Health Organization hepatitis C virus (HCV) elimination targets, it is essential to increase access to direct-acting antivirals (DAAs), especially among people who inject drugs (PWID). We aimed to determine the effectiveness of providing DAAs in primary care, compared with hospital-based specialist care. METHODS: We randomized PWID with HCV attending primary care sites in Australia or New Zealand to receive DAAs at their primary care site or local hospital (standard of care [SOC]). The primary outcome was to determine whether people treated in primary care had a noninferior rate of sustained virologic response at Week 12 (SVR12), compared to historical controls (consistent with DAA trials at the time of the study design); secondary outcomes included comparisons of treatment initiation, SVR12 rates, and the care cascade by study arm. RESULTS: We recruited 140 participants and randomized 136: 70 to the primary care arm and 66 to the SOC arm. The SVR12 rate (100%, 95% confidence interval [CI] 87.7-100) of people treated in primary care was noninferior when compared to historical controls (85% assumed). An intention-to-treat analysis revealed that the proportion of participants commencing treatment in the primary care arm (75%, 43/57) was significantly higher than in the SOC arm (34%, 18/53; P < .001; relative risk [RR] 2.48, 95% CI 1.54-3.95), and the proportion of participants with SVR12 was significantly higher in the primary care arm, compared to in the SOC arm (49% [28/57] and 30% [16/53], respectively; P = .043; RR 1.63, 95% CI 1.0-2.65). CONCLUSIONS: Providing HCV treatment in primary care increases treatment uptake and cure rates. Approaches that increase treatment uptake among PWID will accelerate elimination strategies. CLINICAL TRIALS REGISTRATION: NCT02555475.
Authors: David Ortiz-Paredes; Afia Amoako; Taline Ekmekjian; Kim Engler; Bertrand Lebouché; Marina B Klein Journal: Front Public Health Date: 2022-06-24
Authors: Maria A Corcorran; Judith I Tsui; John D Scott; Julia C Dombrowski; Sara N Glick Journal: Drug Alcohol Depend Date: 2021-01-11 Impact factor: 4.492
Authors: Dena P Blanding; William P Moran; John Bian; Jingwen Zhang; Justin Marsden; Patrick D Mauldin; Don C Rockey; Andrew D Schreiner Journal: J Investig Med Date: 2020-11-17 Impact factor: 2.895
Authors: Andrew Radley; Emma Robinson; Esther J Aspinall; Kathryn Angus; Lex Tan; John F Dillon Journal: BMC Health Serv Res Date: 2019-10-28 Impact factor: 2.655
Authors: H Midgard; A K Finbråten; K B Malme; R M Berg-Pedersen; L Tanum; I C Olsen; R Bjørnestad; O Dalgard Journal: Trials Date: 2020-06-15 Impact factor: 2.279